Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
METHOCARBAMOL AND ASPIRIN vs CHLORZOXAZONE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Methocarbamol is a centrally acting muscle relaxant whose exact mechanism is unknown but may involve general CNS depression. Aspirin irreversibly inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin and thromboxane synthesis, resulting in analgesic, antipyretic, anti-inflammatory, and antiplatelet effects.
Chlorzoxazone acts centrally on the spinal cord and subcortical areas of the brain to inhibit multisynaptic reflex arcs involved in producing and maintaining muscle spasm. It may also have some sedative effects.
Adjunct to rest, physical therapy, and other measures for relief of discomfort associated with acute, painful musculoskeletal conditions,Off-label: relief of muscle spasm in tetanus (methocarbamol component)
Adjunct for relief of acute painful musculoskeletal conditions associated with muscle spasm
1 to 2 tablets (methocarbamol 400 mg / aspirin 325 mg per tablet) orally every 4-6 hours as needed, not to exceed 6 tablets per day.
250-500 mg orally 3-4 times daily, maximum 750 mg 4 times daily.
Methocarbamol: 1–2 hours (terminal). Aspirin: 15–20 minutes for parent drug; salicylic acid: 2–3 hours (low doses) to 15–30 hours (high doses, due to saturable metabolism). Combined product: consider aspirin's longer terminal half-life at therapeutic doses.
Terminal elimination half-life approximately 1–2 hours; clinically relevant for muscle relaxant effect duration.
Methocarbamol is metabolized via dealkylation and hydroxylation, primarily by CYP450 enzymes (CYP2C9, CYP1A2, CYP2D6) and undergoes Phase II conjugation. Aspirin is rapidly hydrolyzed to salicylic acid by esterases in plasma and liver; salicylic acid is primarily conjugated with glycine (salicyluric acid) and glucuronic acid, with minor oxidation.
Hepatic, primarily via CYP2E1, also CYP1A2 and CYP3A4
Methocarbamol: Renal excretion of glucuronide and sulfate conjugates (95%) with <5% unchanged. Aspirin: Renal excretion of salicylic acid and metabolites (primarily salicyluric acid and glucuronides) with ~50% as salicylate at alkaline p H; biliary elimination <5%.
Primarily hepatic metabolism followed by renal excretion of metabolites; <1% excreted unchanged in urine; minor biliary/fecal elimination.
Methocarbamol: 46–50% (mainly albumin). Aspirin: 80–90% (albumin; salicylate binding is concentration-dependent, 50–90%).
Approximately 90–95% bound, primarily to albumin.
Methocarbamol: 0.7–0.8 L/kg (distributes into total body water). Aspirin: 0.15–0.2 L/kg for salicylate at therapeutic doses, increasing to >0.3 L/kg at toxic levels (tissue accumulation).
0.46–0.64 L/kg; indicates distribution into total body water.
Methocarbamol: Oral bioavailability ~100% (well absorbed). Aspirin: Oral bioavailability 40–50% (first-pass hydrolysis to salicylate; enteric-coated forms may have delayed absorption).
Oral: nearly complete; rapidly absorbed with extensive first-pass metabolism; systemic bioavailability approximately 30–50% due to first-pass effect.
Cr Cl <50 m L/min: avoid aspirin component (risk of accumulation and toxicity). Methocarbamol may require cautious use with monitoring. Cr Cl <30 m L/min: contraindicated (aspirin); methocarbamol not recommended.
No specific guidelines; use with caution in severe renal impairment (GFR <30 m L/min) due to potential accumulation of active metabolite.
Child-Pugh Class A: no change. Child-Pugh Class B: reduce dose by 50% or prolong interval. Child-Pugh Class C: contraindicated (risk of bleeding and hepatotoxicity).
Contraindicated in hepatic impairment; avoid use in Child-Pugh class B or C due to risk of hepatotoxicity.
Not recommended in children <12 years due to aspirin's risk of Reye's syndrome. For ≥12 years: same as adult (1-2 tablets every 4-6 hours, max 6 tablets/day).
Not established; safety and efficacy not studied in pediatric patients.
Elderly patients: start with lowest dose (1 tablet every 6 hours) due to increased sensitivity and higher risk of bleeding with aspirin; monitor renal function and consider avoiding chronic use.
Initiate at lower end of dosing range (250 mg 3-4 times daily); monitor for CNS effects (dizziness, drowsiness) and liver function.
Reye's syndrome: Aspirin should not be used in children or teenagers with viral infections due to risk of Reye's syndrome.
None
Salicylate toxicity (tinnitus, hyperventilation, metabolic acidosis); bleeding risk (aspirin antiplatelet effect); hepatic impairment; renal impairment; GI bleeding; pregnancy (avoid in third trimester); nursing mothers; hypersensitivity to NSAIDs; concomitant use of methotrexate or anticoagulants; Reye's syndrome risk in pediatric viral illness.
May cause drowsiness, dizziness, or impaired coordination. Caution in patients with hepatic impairment. Discontinue if hypersensitivity reactions occur. Avoid concurrent use with alcohol or other CNS depressants.
Hypersensitivity to methocarbamol, aspirin, or any component; children and teenagers with or recovering from viral illness (Reye's syndrome); third trimester of pregnancy; bleeding disorders (e.g., hemophilia); active peptic ulcer; severe renal impairment; concomitant use of methotrexate (≥15 mg/week) or oral anticoagulants (relative).
Hypersensitivity to chlorzoxazone or any component of the formulation; impaired hepatic function
Avoid alcohol (increases CNS depression and GI bleeding risk). Take with food or milk to minimize gastric irritation. Avoid high-dose vitamin C or acidic foods that may increase aspirin absorption and toxicity.
No significant food interactions. Take with or without food. Grapefruit juice may increase drug levels; avoid large quantities.
First trimester: Aspirin is associated with increased risk of miscarriage and congenital malformations (e.g., gastroschisis) at high doses; methocarbamol has limited data, but no major teratogenicity reported. Second trimester: Aspirin may cause premature closure of ductus arteriosus at high doses; methocarbamol safety uncertain. Third trimester: Aspirin increases risk of intracranial hemorrhage in neonate and premature closure of ductus arteriosus; avoid use after 30 weeks. Methocarbamol: no known specific fetal risks, but avoid in late pregnancy due to potential maternal muscle relaxation effects.
Teratogenic risk in humans is not well-studied. No major teratogenic effects have been reported in animal studies. However, as with all medications, use during pregnancy only if clearly needed and after weighing risks vs. benefits. Avoid during first trimester unless necessary.
Aspirin is excreted into breast milk with an M/P ratio of 0.6-1.0; potential for Reye syndrome or platelet dysfunction in infant at high doses. Methocarbamol excretion unknown; no adverse effects reported. Use with caution, especially with high-dose aspirin.
Not recommended during breastfeeding due to potential for sedation in the infant. No M/P ratio data available.
No specific pharmacokinetic changes reported for methocarbamol in pregnancy. For aspirin, increased renal clearance in pregnancy may require higher doses for anti-inflammatory effect, but doses >325 mg/day are avoided due to fetal risks. Use lowest effective dose, not exceeding 100 mg/day in third trimester.
No dosage adjustment specific to pregnancy is required based on pharmacokinetic data; however, clinical response should be monitored.
Methocarbamol is a centrally acting muscle relaxant; aspirin is an NSAID. Onset of methocarbamol is rapid (30 min) with peak at 2 hours. Aspirin component may increase bleeding risk, especially with alcohol or anticoagulants. Avoid in children with viral illness due to Reye's syndrome risk. Max aspirin dose 4g/day.
Chlorzoxazone is a centrally acting muscle relaxant used for acute musculoskeletal pain. Onset of action is within 1 hour; peak effect at 1-2 hours. Monitor for hepatotoxicity, especially with prolonged use or high doses. Can cause drowsiness and impair motor skills; avoid concurrent use with alcohol or other CNS depressants. Tablets may be crushed for patients with swallowing difficulties.
Take with food to reduce GI upset.,Avoid alcohol and other CNS depressants.,May cause drowsiness or dizziness; avoid driving.,Do not use in children or teenagers with chickenpox or flu symptoms.,Stop and seek medical attention if signs of bleeding or allergic reaction occur.
Take exactly as prescribed; do not increase dose or frequency.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Avoid alcohol and other CNS depressants while taking this medication.,Report signs of liver problems: dark urine, yellowing of eyes/skin, persistent nausea, abdominal pain.,Do not suddenly stop taking if used long-term; taper under medical supervision to avoid withdrawal.
"The coadministration of propofol, a GABA-A receptor agonist general anesthetic, with methocarbamol, a centrally acting muscle relaxant, can produce additive sedative and respiratory depressant effects. This interaction may lead to excessive sedation, prolonged recovery from anesthesia, and an increased risk of hypoxia or apnea. Clinically, patients may exhibit deeper levels of unconsciousness and require prolonged monitoring of respiratory function."
"Methocarbamol, a centrally acting muscle relaxant, potentiates the sedative effects of nabilone, a synthetic cannabinoid used for chemotherapy-induced nausea and vomiting. This additive central nervous system depression can lead to excessive drowsiness, dizziness, impaired motor coordination, and increased risk of falls or cognitive impairment. Clinically, patients may experience exacerbated sedation, confusion, and psychomotor slowing, particularly when initiating therapy or at higher doses."
"Concomitant use of methocarbamol and gabapentin enacarbil results in additive central nervous system (CNS) depression due to their shared pharmacodynamic effects on GABAergic neurotransmission and neuronal excitability. This synergistic interaction significantly increases the risk of excessive sedation, dizziness, and impaired psychomotor function, potentially leading to falls, cognitive deficits, or respiratory depression in susceptible patients. Clinical outcomes are dose-dependent and more pronounced in elderly patients or those with pre-existing CNS compromise."
"Lumacaftor is a strong inducer of cytochrome P450 (CYP) 3A4 and other drug-metabolizing enzymes, including CYP2E1. Chlorzoxazone is primarily metabolized by CYP2E1 to its inactive metabolite. Concomitant use increases CYP2E1 activity, leading to accelerated chlorzoxazone clearance and reduced systemic exposure, potentially diminishing its therapeutic effect as a muscle relaxant."
"Chlorzoxazone, a centrally acting muscle relaxant, inhibits the metabolism of diltiazem, a calcium channel blocker, via competitive inhibition of CYP3A4. This leads to increased plasma concentrations of diltiazem, potentially causing enhanced negative chronotropic and vasodilatory effects, resulting in bradycardia, hypotension, or atrioventricular block. Patients may experience dizziness, syncope, or exacerbate heart failure symptoms."
"Butalbital, a barbiturate, induces hepatic cytochrome P450 enzymes (particularly CYP2E1), accelerating the metabolism of chlorzoxazone, a centrally acting muscle relaxant primarily metabolized by CYP2E1. This results in reduced plasma concentrations of chlorzoxazone, leading to diminished therapeutic efficacy and potential loss of symptom control. Clinically, patients may experience inadequate muscle relaxation, requiring dose adjustments or alternative therapy."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about METHOCARBAMOL AND ASPIRIN vs CHLORZOXAZONE, answered by our medical review team.
METHOCARBAMOL AND ASPIRIN is a Skeletal Muscle Relaxant that works by Methocarbamol is a centrally acting muscle relaxant whose exact mechanism is unknown but may involve general CNS depression. Aspirin irreversibly inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin and thromboxane synthesis, resulting in analgesic, antipyretic, anti-inflammatory, and antiplatelet effects.. CHLORZOXAZONE is a Skeletal Muscle Relaxant that works by Chlorzoxazone acts centrally on the spinal cord and subcortical areas of the brain to inhibit multisynaptic reflex arcs involved in producing and maintaining muscle spasm. It may also have some sedative effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between METHOCARBAMOL AND ASPIRIN and CHLORZOXAZONE depend on the specific clinical indication. These are both Skeletal Muscle Relaxant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of METHOCARBAMOL AND ASPIRIN is: 1 to 2 tablets (methocarbamol 400 mg / aspirin 325 mg per tablet) orally every 4-6 hours as needed, not to exceed 6 tablets per day.. The standard adult dose of CHLORZOXAZONE is: 250-500 mg orally 3-4 times daily, maximum 750 mg 4 times daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining METHOCARBAMOL AND ASPIRIN and CHLORZOXAZONE. The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Methocarbamol. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. METHOCARBAMOL AND ASPIRIN is classified as Category A/B. First trimester: Aspirin is associated with increased risk of miscarriage and congenital malformations (e.g., gastroschisis) at high doses; methocarbamol has limited data, but no m. CHLORZOXAZONE is classified as Category C. Teratogenic risk in humans is not well-studied. No major teratogenic effects have been reported in animal studies. However, as with all medications, use during pregnancy only if cl. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.